Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer

Table 1 Characteristics of the patients

Characteristic	Value
Age, years
Median	58
Range	31–72
Sex
Male	22(66.7)
Female	11(33.3)
ECOG performance status
0	13(39.4)
1	14(42.4)
2	5(15.2)
3	1(3.0)
Smoking History
Smoker	14(42.4)
Non-smoker*	19(57.6)
Histology
Adenocarcinoma	24(72.7)
Squamous cell carcinoma	9(27.3)
Stage at study entry
III B	10(30.3)
IV	23(69.7)
No. of Prior failed chemotherapy regimen
0	12(36.4)
1	13(39.4)
≥2	8(24.2)
Chemotherapy response prior to gefitinib
MR	7(21.2%)
PR	26(78.8%)

*Non-smoker = patients who had smoked less than 100 cigarettes in their lifetime.

ISSN: 1471-2407